Literature DB >> 30448002

Survival impact of radiotherapy interruption in nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis.

Ji-Jin Yao1, Fan Zhang2, Tian-Sheng Gao3, Wang-Jian Zhang4, Wayne R Lawrence4, Bao-Ting Zhu5, Guan-Qun Zhou5, Jun Ma5, Si-Yang Wang6, Ying Sun7.   

Abstract

PURPOSE: To evaluate the effect of radiotherapy interruption (RTI) in patients with nasopharyngeal carcinoma (NPC) receiving intensity-modulated radiotherapy (IMRT). PATIENTS AND METHODS: A total of 7826 patients using the well-established big-data intelligence platform were identified. Computer-generated random numbers were used to assign these patients into a training cohort (n = 3913 patients) and an internal validation cohort (n = 3913 patients). RTI was defined as the difference between radiation treatment time and planned radiation time (assuming a Monday start). Survival analysis was performed using the Kaplan-Meier method for survival, and log-rank test to evaluate difference. Optimal RTI threshold was identified using the recursive partitioning analyses (RPAs). Multivariate analysis was performed using the Weibull model. The primary endpoint was overall survival (OS).
RESULTS: The optimal threshold of RTI with respect to OS in the training cohort was 6.5 d based on RPAs. Therefore, a uniform threshold of 7 d (<7 vs. ≥7 d) was selected to classify both training and validation cohorts into high and low RTI groups for survival analysis. RTI of ≥7 d showed significant detrimental effects on OS in both training (5-y OS, 82.4% vs 86.5%; P = 0.001) and validation cohorts (5-y OS, 85.2% vs 86.7%; P = 0.013) than those patients with RTI of <7 d. Consistent with results of the univariate analysis, RTI of ≥7 d was found to be an independent unfavorable prognostic factor for OS in both training (HR, 1.49; 95% CI, 1.14-1.95; P = 0.003) and validation cohort (HR, 1.37; 95% CI, 1.07-1.65; P = 0.031). Subgroup analysis showed that RTI of ≥7 d had significant adverse effects on prognosis of NPC patients receiving IMRT, regardless of TNM stage and chemotherapy (P < 0.05 for all).
CONCLUSIONS: In the IMRT era, RTI independently influences survival. Raising RTI ≥ 7 d was consistently unfavorable for NPC survival. Medical practitioners must remind patients on the importance of minimizing RT interruptions.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Intensity-modulated radiotherapy; Nasopharyngeal carcinoma; Optimal threshold; Prognostic impact; Radiotherapy interruption

Mesh:

Year:  2018        PMID: 30448002     DOI: 10.1016/j.radonc.2018.10.018

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  10 in total

1.  Suggestions for radiation oncologists to overcome radiotherapy interruption in patients with nasopharyngeal cancer.

Authors:  Jung Ae Lee; Won Sup Yoon
Journal:  Ann Transl Med       Date:  2019-09

2.  Development and implementation of a dynamically updated big data intelligence platform from electronic health records for nasopharyngeal carcinoma research.

Authors:  Li Lin; Wei Liang; Chao-Feng Li; Xiao-Dan Huang; Jia-Wei Lv; Hao Peng; Bing-Yi Wang; Bo-Wei Zhu; Ying Sun
Journal:  Br J Radiol       Date:  2019-08-20       Impact factor: 3.039

3.  The hidden curve behind COVID-19 outbreak: the impact of delay in treatment initiation in cancer patients and how to mitigate the additional risk of dying-the head and neck cancer model.

Authors:  Leandro L Matos; Carlos Henrique Q Forster; Gustavo N Marta; Gilberto Castro Junior; John A Ridge; Daisy Hirata; Adalberto Miranda-Filho; Ali Hosny; Alvaro Sanabria; Vincent Gregoire; Snehal G Patel; Johannes J Fagan; Anil K D'Cruz; Lisa Licitra; Hisham Mehanna; Sheng-Po Hao; Amanda Psyrri; Sandro Porceddu; Thomas J Galloway; Wojciech Golusinski; Nancy Y Lee; Elcio H Shiguemori; José Elias Matieli; Ana Paula A C Shiguemori; Letícia R Diamantino; Luiz Felipe Schiaveto; Lysia Leão; Ana F Castro; André Lopes Carvalho; Luiz Paulo Kowalski
Journal:  Cancer Causes Control       Date:  2021-03-11       Impact factor: 2.506

4.  Consolidation Immunotherapy After Platinum-Based Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer-Cross-Sectional Study of Eligibility and Administration Rates.

Authors:  Tanja Eichkorn; Farastuk Bozorgmehr; Sebastian Regnery; Lisa A Dinges; Andreas Kudak; Nina Bougatf; Dorothea Weber; Petros Christopoulos; Thomas Muley; Sonja Kobinger; Laila König; Juliane Hörner-Rieber; Sebastian Adeberg; Claus Peter Heussel; Michael Thomas; Jürgen Debus; Rami A El Shafie
Journal:  Front Oncol       Date:  2020-12-01       Impact factor: 6.244

5.  Epidemiological Profile and Clinicopathological, Therapeutic, and Prognostic Characteristics of Nasopharyngeal Carcinoma in Northern Morocco.

Authors:  Ayman Reffai; Mohamed Mesmoudi; Touria Derkaoui; Naima Ghailani Nourouti; Amina Barakat; Nabila Sellal; Parag Mallick; Mohcine Bennani Mechita
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

6.  Management and Outcomes of Patients With Radiotherapy Interruption During the COVID-19 Pandemic.

Authors:  Xiaofang Ying; Jianping Bi; Yi Ding; Xueyan Wei; Wei Wei; Fang Xin; Chuangying Xiao; Desheng Hu; Vivek Verma; Guang Han
Journal:  Front Oncol       Date:  2021-11-19       Impact factor: 6.244

7.  The prognostic value of weight loss during radiotherapy among patients with nasopharyngeal carcinoma: a large-scale cohort study.

Authors:  Ya-Nan Jin; Tian-Liang Xia; Dong-Mei Mai; Ji-Jin Yao; Chang Jiang; Wen-Zhuo He; Liang-Ping Xia
Journal:  BMC Cancer       Date:  2022-05-06       Impact factor: 4.638

8.  Emergency changes in international guidelines on treatment for head and neck cancer patients during the COVID-19 pandemic.

Authors:  Aline Lauda Freitas Chaves; Ana Ferreira Castro; Gustavo Nader Marta; Gilberto Castro Junior; Robert L Ferris; Raúl Eduardo Giglio; Wojciech Golusinski; Philippe Gorphe; Sefik Hosal; C René Leemans; Nicolas Magné; Hisham Mehanna; Ricard Mesía; Eduardo Netto; Amanda Psyrri; Assuntina G Sacco; Jatin Shah; Christian Simon; Jan B Vermorken; Luiz Paulo Kowalski
Journal:  Oral Oncol       Date:  2020-04-24       Impact factor: 5.337

9.  Missed radiation therapy sessions in first three weeks predict distant metastasis and less favorable outcomes in surgically treated patients with oral cavity squamous cell carcinoma.

Authors:  Yin-Yin Chiang; Yung-Chih Chou; Kai-Ping Chang; Chun-Ta Liao; Yao-Yu Wu; Wing-Keen Yap; Ping-Ching Pai; Joseph Tung-Chieh Chang; Chien-Yu Lin; Kang-Hsing Fan; Bing-Shen Huang; Tsung-Min Hung; Ngan-Ming Tsang
Journal:  Radiat Oncol       Date:  2020-08-14       Impact factor: 3.481

10.  Prognostic value of radiation interruption in different periods for nasopharyngeal carcinoma patients in the intensity-modulated radiation therapy era.

Authors:  Xing-Li Yang; Guan-Qun Zhou; Li Lin; Lu-Lu Zhang; Fo-Ping Chen; Jia-Wei Lv; Jia Kou; Dan-Wan Wen; Jun Ma; Ying Sun; Yan-Ping Mao
Journal:  Cancer Med       Date:  2020-10-27       Impact factor: 4.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.